Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) has shared an update.
On February 25, 2025, Radiopharm Theranostics Limited announced changes in its director’s interest and the cessation of certain securities. Specifically, Director Ian Turner acquired 1,300,000 shares indirectly through a superannuation fund on February 19, 2025, increasing his total holdings to 6,255,292 shares and 18,988,350 options. This change reflects the company’s ongoing adjustments in its executive’s investment positions, potentially impacting shareholder perceptions and market dynamics.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited operates in the healthcare industry, focusing on the development of radiopharmaceutical products. The company is involved in the production and commercialization of innovative diagnostic and therapeutic solutions, primarily targeting cancer treatment and diagnosis.
Average Trading Volume: 74,899
Current Market Cap: $35.54M
Find detailed analytics on RADX stock on TipRanks’ Stock Analysis page.